Which Country Is Adcetris (Brentuximab Vedotin) Cheapest In? — 2026 Guide

Why does the price differ so much between countries?

Adcetris (brentuximab vedotin) is a CD30-directed antibody–drug conjugate that delivers the microtubule poison MMAE into malignant lymphocytes, approved for classical Hodgkin lymphoma and systemic anaplastic large cell lymphoma, both used in combination regimens and as consolidation after stem-cell transplant. It is supplied as a 50 mg single-use lyophilised vial that a hospital pharmacist must reconstitute and dilute before intravenous infusion — there is no oral or take-home form, so Adcetris is dispensed to the treating oncology unit, never sold across a retail counter in any country. A structural quirk unique among the three drugs compared here is that Adcetris is commercialised by two different companies in two different territories: Pfizer, through its Seagen acquisition, holds US rights, while Takeda holds rights across the rest of the world, including Europe, Türkiye and most of Asia. That split means launch timing, list-price setting and even formulary negotiations are genuinely separate commercial decisions rather than one manufacturer's global strategy, which is itself a real driver of the price and availability differences seen between the US and other markets.

In Türkiye, the Ministry of Health anchors the Takeda-supplied reference price to the lowest ex-factory price found in a designated basket of EU member states, then converts it using the "pharmaceutical euro" (Dönemsel Avro Değeri), fixed at 65% of the prior year's average Central Bank euro rate rather than the live spot rate. That mechanism, published via the TİTCK price list and gazetted in the Resmî Gazete, is the principal reason Turkish list prices for complex ADCs like Adcetris sit structurally below list prices in free-pricing markets, independent of who happens to hold the regional licence.

Germany applies its AMNOG framework to Takeda's Adcetris: a free manufacturer-set price applies for the first six months after launch of any new indication, after which a negotiated price agreed with the GKV-Spitzenverband applies, backdated to month seven rather than to the original launch date. The UK's NICE evaluates cost-effectiveness against a cost-per-QALY threshold that has just been raised from the long-standing £20,000–£30,000 band to £25,000–£35,000, announced 1 December 2025 and taking effect from April 2026 (see NICE); a higher ceiling changes what counts as cost-effective for a lymphoma ADC without being a price itself. Because brentuximab vedotin has no approved biosimilar in any market, there is no generic-entry price collapse to offset either mechanism.

The United States, where Pfizer/Seagen holds the licence, has no equivalent government reference mechanism: pricing is essentially free at launch and negotiated privately between the manufacturer, payers and pharmacy benefit managers, a structural gap documented broadly (not drug-specifically) by the RAND Corporation's 2022 international price comparison, published 1 February 2024. Because Adcetris is hospital-administered everywhere, most institutions never pay the headline list price regardless of jurisdiction; they procure through tenders and confidential discounts, so any list-price comparison, including this one, reflects published reference figures rather than actual acquisition cost. For the underlying mechanics of why Türkiye's published prices sit where they do, see our explainer on why medicines cost less in Türkiye.

How is the price set in each country?

The table below compares pricing systems, not prices. Each country publishes — or does not publish — its own official list, and that published list is the only figure worth relying on. Follow the link in the last column and read the current entry yourself.

How can I obtain a medicine legally from a lower-price market?

There is a lawful route in most countries, and it starts in the same place everywhere: a valid prescription in your own name, issued by the physician treating you. What differs is the import permit. The procedures below are stated only where they could be verified at the national authority.

United Arab Emirates. MOHAP operates a permit to import medicines for personal use through its Electronic Drug Establishment service. The permit is free and is issued within 3 working days. You log in with a MOHAP account or UAE Pass.

Saudi Arabia. Applications run through the SFDA Controlled Drugs System at cds.sfda.gov.sa, under a guideline published on 14 August 2025. Read the current SFDA regulations page before you travel — the requirements are revised periodically.

Qatar. For non-controlled medicines there is no pre-approval: you may carry up to a 60-day supply through the Green Channel, in the original packaging, with a copy of the prescription and a signed, stamped letter from your doctor. For controlled medicines you need advance approval and must use the Red Channel; supporting documents must be no older than 6 months and in Arabic or English.

Kuwait and Azerbaijan. Confirm the current procedure directly with the national authority before shipping or travelling — Kuwait Ministry of Health and Azerbaijan Tariff Council. We do not publish a step list for these two countries because the procedure could not be verified at source.

1. United Arab Emirates — obtain a prescription in the applicant's own name, issued within the last 3 months.
2. Obtain a medical report from the treating facility, authenticated by the health authority and issued within the last year.
3. Prepare an Emirates ID or passport copy for the applicant.
4. Log in to the MOHAP service with a MOHAP account or UAE Pass and submit the personal-import application.
5. Keep the quantity within the limit: no more than a 1-month supply for controlled medicines, and no more than a 3-month supply for non-controlled medicines.
6. Wait for the decision — the service is free and normally issued within 3 working days.
7. Contact MOHAP on 800 111 11 or at import.export@mohap.gov.ae if the application stalls.

What is named patient supply?

Named patient supply is the international concept behind almost every lawful cross-border medicine route. The clearest codified example is the United Kingdom's MHRA Guidance Note 14, built on Regulation 167 of the Human Medicines Regulations 2012.

Four conditions define it: the order must be unsolicited; the product must be specified by the prescriber; the prescriber must be directly responsible for the patient; and there must be a genuine special clinical need that no authorised product meets.

The honesty point matters here: the European Court has held that "financial considerations cannot, in themselves" establish a special clinical need. A lower price in another country is not, by itself, a lawful basis for a named-patient import. The lawful bases are clinical.

Is the Adcetris I'm being offered genuine?

No falsified batches of Adcetris have been recorded in the WHO's medical product alert series to date. That clean record reflects both its narrow, specialist-only distribution through hospital oncology and haematology units and the fact that a dual-manufacturer commercialisation structure (Pfizer/Seagen in the US, Takeda elsewhere) means each region's authorised supply chain is independently monitored, leaving little room for the informal secondary markets where falsification typically surfaces.

Because Adcetris crosses between two separate corporate supply chains depending on territory, patients or clinicians sourcing it across borders should pay particular attention to which company's authorised distributor actually supplied the vial for their region, rather than assuming a single global chain of custody.

• Scan the carton's GS1 DataMatrix and confirm it decodes to AI 01 (GTIN), AI 21 (serial number), AI 17 (expiry) and AI 10 (batch) — a code that won't scan, or scans to the wrong product, is a hard stop.
• If the vial is sourced in Türkiye, check that its karekod is notified to the national İlaç Takip Sistemi (İTS) track-and-trace system at its.saglik.gov.tr before it leaves the pharmacy.
• Confirm whether the vial should carry Takeda or Pfizer/Seagen branding for your region, since a mismatch between the packaging's manufacturer and the territory you're in is itself a red flag given the split commercialisation.
• Request a continuous 2–8°C temperature log covering the actual shipment received, not a generic cold-chain certificate — Adcetris must never be frozen or vigorously shaken.
• Confirm reconstitution and dilution were performed only by hospital pharmacy staff following the approved preparation protocol; Adcetris is never a self-administered or take-home product.
• Cross-check the batch and lot number against the WHO's live list at our WHO falsified medicine alerts tracker before administration, even though no Adcetris-specific alert exists at present.
• Review the full verification workflow in our guide to checking that a medicine is genuine.

Frequently asked questions

Sources

• Resmî Gazete — Beşeri Tıbbi Ürünlerin Fiyatlandırılmasına Dair Karar No. 11031 — retrieved: 2026-07-28
• TİTCK — published medicine price list — retrieved: 2026-07-28
• MOHAP (UAE) — import medicine for personal use — retrieved: 2026-07-28
• SFDA (Saudi Arabia) — regulations — retrieved: 2026-07-28
• SFDA Controlled Drugs System — retrieved: 2026-07-28
• Qatar MOPH — drug prices — retrieved: 2026-07-28
• Kuwait Ministry of Health — retrieved: 2026-07-28
• Azerbaijan Tariff Council (Tarif Şurası) — retrieved: 2026-07-28
• NICE (United Kingdom) — retrieved: 2026-07-28
• G-BA (Germany) — AMNOG benefit assessment — retrieved: 2026-07-28
• RAND — International prescription drug price comparisons (published 1 Feb 2024) — retrieved: 2026-07-28
• Frontiers in Pharmacology — European hospital price transparency study (9 Mar 2026) — retrieved: 2026-07-28
• MHRA Guidance Note 14 — supply of unlicensed medicinal products — retrieved: 2026-07-28

Country availability pages for this medicine

Related pages

Antibody–drug conjugates

Related high-cost medicines